We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, ta... read more Featured Products: More products

Download Mobile App




Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up

By LabMedica International staff writers
Posted on 20 Apr 2026

Sexually transmitted infections (STIs) are often asymptomatic, and reliance on clinic-based testing can delay diagnosis and treatment. More...

More than one million curable infections are acquired daily worldwide among people aged 15–49, and complications contribute to infertility in nearly 100,000 women in the United States each year. Faster access to accurate diagnostics remains a critical clinical need. Addressing this need, a new partnership will expand access to an at-home PCR test that delivers lab-quality results in about 30 minutes with integrated virtual follow-up.

Visby Medical’s Women’s Sexual Health PCR test, an U.S. Food and Drug Administration (FDA)-authorized at-home PCR STI test, will be offered through a collaboration with Wisp, a U.S. women’s telehealth platform. The program will begin with targeted patient outreach, with plans to expand access over time. When results are positive for chlamydia, gonorrhea, or trichomoniasis, patients are referred to Wisp for follow-up telehealth care.

The palm-sized device performs PCR and reports results within 30 minutes via Visby’s mobile app. The integrated model is intended to streamline the path from diagnosis to treatment compared with conventional care pathways. For those who test positive, Wisp provides a complimentary virtual consultation with a licensed provider, and antibiotics can be prescribed from home when clinically appropriate.

The collaboration emphasizes discreet access to testing and timely clinical guidance. Wisp’s platform supports secure online consultations, personalized care plans, and confidential treatment pathways. The at-home test is also eligible for flexible spending account and health savings account reimbursement, and the partners plan to broaden availability while continuing to reduce time between diagnosis and treatment.

“This partnership came directly from listening to our patients,” said Monica Cepak, CEO of Wisp. “Women are asking for faster answers and more seamless next steps. By pairing Visby’s FDA-authorized at-home PCR test with Wisp’s care model, we’re delivering on our mission to support women across every life stage with fast, private, and stigma-free care.”

“By providing timely medical advice through telehealth, the value of the Visby at-home sexual health test significantly increases,” said Dr. Gary Schoolnik, Chief Medical Officer at Visby Medical and Professor of Medicine at Stanford Medical School. “This ensures that women who use the Visby test will receive prompt and effective advice and a path to treatment, if indicated.”


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
POC Immunoassay Analyzer
Procise DX
New
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.